Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs Nova MD

Medro
Graded #252

Lower grade

vs+3.3000000000000043
Nova MD
Graded #174

Higher grade

The verdict

Nova MD takes it — 66.9/100 to 63.6/100.

Nova MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNova MD +18
50
68
Dose & formulationMedro +13
77
64
Clinical oversightNova MD +11
71
82
Labs & monitoringNova MD +2
52
54
FulfillmentMedro +24
92
68
Contract termsNova MD +22
33
55
Medro · left barNova MD · right bar

The numbers

MetricMedroNova MD
WeighScore63.6/10066.9/100
GradeCC
Scorecard rank#252#174
Semaglutide$199/mo (compounded)$175/mo (compounded)
Tirzepatide$299/mo (compounded)$225/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Nova MD

Graded #174 · C

Strengths

  • On-page pricing published for all four SKUs (semaglutide and tirzepatide, 1- and 3-month)
  • $125/mo semaglutide and $199/mo tirzepatide 3-month plans rank among the cheapest in the market
  • $50 off first tirzepatide order shown publicly
  • Explicit microdose / low-dose program for both semaglutide and tirzepatide
  • Broader menu (sermorelin, NAD+, glutathione, enclomiphene) for longevity alongside GLP-1

Where it loses points

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy not named — only 'accredited facilities'
  • LegitScript certification not confirmed (only 'Licensed US Providers' claims)
  • Per-state availability not listed
  • Compounded only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard